BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19921960)

  • 21. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma.
    Fish JE; Karpel JP; Craig TJ; Bensch GW; Noonan M; Webb DR; Silverman B; Schenkel EJ; Rooklin AR; Ramsdell JW; Nathan R; Leflein JG; Grossman J; Graft DF; Gower RG; Garay SM; Frigas E; Degraff AC; Bronsky EA; Bernstein DI; Berger W; Shneyer L; Nolop KB; Harrison JE
    J Allergy Clin Immunol; 2000 Nov; 106(5):852-60. PubMed ID: 11080706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term safety of mometasone furoate administered via a dry powder inhaler in children: Results of an open-label study comparing mometasone furoate with beclomethasone dipropionate in children with persistent asthma.
    Noonan M; Leflein J; Corren J; Staudinger H
    BMC Pediatr; 2009 Jul; 9():43. PubMed ID: 19594937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg and 400/10 microg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids.
    Weinstein SF; Corren J; Murphy K; Nolte H; White M;
    Allergy Asthma Proc; 2010; 31(4):280-9. PubMed ID: 20687982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma.
    Hansel TT; Benezet O; Kafé H; Ponitz HH; Cheung D; Engelstätter R; Barnes PJ
    Clin Ther; 2006 Jun; 28(6):906-20. PubMed ID: 16860173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of inhaled mometasone furoate on growth velocity and adrenal function: a placebo-controlled trial in children 4-9 years old with mild persistent asthma.
    Skoner DP; Meltzer EO; Milgrom H; Stryszak P; Teper A; Staudinger H
    J Asthma; 2011 Oct; 48(8):848-59. PubMed ID: 21854342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
    Medley H; Orozco S; Allen A
    Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy and safety of mometasone furoate delivered via a dry powder inhaler for the treatment of asthma.
    Meltzer EO; Wenzel S
    J Asthma; 2006 Dec; 43(10):765-72. PubMed ID: 17169829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of mometasone furoate administered via a dry powder inhaler in the treatment of asthma.
    Zeidler M; Corren J; Tashkin DP
    Curr Med Res Opin; 2010 Jun; 26(6):1295-305. PubMed ID: 20370376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler.
    Bousquet J; D'Urzo A; Hebert J; Barraza CH; Boulet LP; Suárez-Chacón R; Harnest U; Lundbäck B; Martinez Morales G; Nieminen MM; Nolop KB; Visser S; Lutsky BN
    Eur Respir J; 2000 Nov; 16(5):808-16. PubMed ID: 11153576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mometasone furoate dry-powder inhaler for the control of persistent asthma.
    D'Urzo A
    Expert Opin Pharmacother; 2007 Nov; 8(16):2871-84. PubMed ID: 17956206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids.
    Nathan RA; Nolte H; Pearlman DS;
    Allergy Asthma Proc; 2010; 31(4):269-79. PubMed ID: 20678306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
    Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma.
    LaForce CF; Pearlman DS; Ruff ME; Silvers WS; Weinstein SW; Clements DS; Brown A; Duke S; Harding SM; House KW
    Ann Allergy Asthma Immunol; 2000 Nov; 85(5):407-15. PubMed ID: 11101186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the efficacy of ciclesonide 160 microg QD and budesonide 200 microg BID in adults with persistent asthma: a phase III, randomized, double-dummy, open-label study.
    Niphadkar P; Jagannath K; Joshi JM; Awad N; Boss H; Hellbardt S; Gadgil DA
    Clin Ther; 2005 Nov; 27(11):1752-63. PubMed ID: 16368446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extrafine beclomethasone dipropionate breath-actuated inhaler (400 micrograms/day) versus budesonide dry powder inhaler (800 micrograms/day) in asthma.
    Reichel W; Dahl R; Ringdal N; Zetterstrom O; van den Elshout FJ; Laitinen LA
    Int J Clin Pract; 2001 Mar; 55(2):100-6. PubMed ID: 11321849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bronchodilation with mometasone furoate/formoterol fumarate administered by metered-dose inhaler with and without a spacer in children with persistent asthma.
    Berger WE; Bensch GW; Weinstein SF; Skoner DP; Prenner BM; Shekar T; Nolte H; Teper AA
    Pediatr Pulmonol; 2014 May; 49(5):441-50. PubMed ID: 24019197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study.
    Price D; Robertson A; Bullen K; Rand C; Horne R; Staudinger H
    BMC Pulm Med; 2010 Jan; 10():1. PubMed ID: 20051135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250 microg) combination product (SAS 40023).
    Baumgarten C; Geldszus R; Behre U; Peslis N; Trautmann M;
    Eur J Med Res; 2002 Jan; 7(1):1-7. PubMed ID: 11827834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Once-daily evening dosing of mometasone furoate administered via a dry powder inhaler does not adversely affect the hypothalamic-pituitary-adrenal axis.
    Kosoglou T; Cutler DL; Staudinger H; Herron JM
    Chest; 2010 Jan; 137(1):115-21. PubMed ID: 19749003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhaled mometasone furoate reduces oral prednisone usage and improves lung function in severe persistent asthma.
    Karpel JP; Nayak A; Lumry W; Craig TJ; Kerwin E; Fish JE; Lutsky B
    Respir Med; 2007 Mar; 101(3):628-37. PubMed ID: 16875813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.